Table of contents
  1. Learning objectives
  2. What the procedure is
  3. Basic procedural steps
  4. What are the goals of the procedure?
  5. Hemodynamic goal
  6. Goal by indication
  7. When TIPS is most often used
  8. High-yield U.S.-supported indications
  9. Who is less likely to do well after TIPS
  10. Major reasons to avoid elective TIPS
  11. MELD and candidacy
  12. Immediate and early procedural risks
  13. Procedure-related complications
  14. Delayed complications after TIPS
  15. 1) Hepatic encephalopathy
  16. 2) Post-TIPS liver failure
  17. 3) Cardiac decompensation
  18. 4) TIPS dysfunction
  19. Pre-TIPS evaluation that most changes outcomes
  20. Cardiac thresholds that should slow or stop elective TIPS
  21. Post-TIPS care and surveillance
  22. Practical bedside takeaways
  23. References

GI/Hepatology · Hepatology Topics

Transjugular Intrahepatic Portosystemic Shunt (TIPS)

Back to GI/Hepatology →Open presenter mode

TIPS: Procedure Basics, Hemodynamic Goals, and Complications

TIPS is an image-guided portosystemic shunt created between a hepatic vein and an intrahepatic portal vein branch to decompress portal hypertension. Clinically, it is most useful for selected patients with high-risk or uncontrolled variceal bleeding and for carefully chosen patients with recurrent or refractory ascites or hepatic hydrothorax. In current U.S. guidance, the key is not only whether TIPS can lower portal pressure, but whether the patient can tolerate the physiologic consequences of shunting. (Lee 2024, Kaplan 2024, Biggins 2021, Boike 2022)

Learning objectives

  • Describe how a TIPS is created and what it does hemodynamically.
  • Apply indication-specific procedural goals, including portal pressure gradient targets.
  • Recognize the major immediate and delayed complications after TIPS.
  • Identify which patients are less likely to do well after TIPS.
  • Use U.S.-based guidance to frame MELD, cardiac risk, and encephalopathy risk in TIPS decision-making.

What the procedure is

A TIPS is a low-resistance channel created between the portal venous and hepatic venous systems so that portal blood can bypass the cirrhotic liver and return more directly to the systemic circulation. This lowers portal pressure and reduces complications driven by portal hypertension. (Musto 2022, Boike 2022)

Basic procedural steps

Picture3 1
  • Venous access is usually obtained through the right internal jugular vein.
  • A catheter is advanced into the right or middle hepatic vein.
  • The portal vein is targeted from the hepatic vein, often with fluoroscopic guidance and sometimes with intravascular ultrasound or CO2 portography.
  • The intrahepatic tract is created, dilated, and then lined with a covered stent graft.
  • Portal and systemic venous pressures are measured before and after shunt creation to calculate the portosystemic gradient (PSG). (Musto 2022, Boike 2022)
  • Use an ePTFE-lined covered stent graft, ideally with controlled expansion, so the operator can tailor the amount of shunting to the indication and comorbidity profile. (Boike 2022)
  • When measuring the PSG, use the free hepatic vein pressure or IVC pressure as the systemic pressure rather than right atrial pressure. (Boike 2022)
  • In patients who may later undergo transplant, the stent should be positioned so it does not extend into the right atrium and leaves a usable segment of portal vein for future anastomosis. (Boike 2022)

What are the goals of the procedure?

Hemodynamic goal

The immediate goal is to decompress the portal venous system enough to prevent or improve the portal hypertensive complication, while avoiding overshunting that increases the risk of encephalopathy, liver failure, or cardiac decompensation. (Boike 2022)

Goal by indication

Variceal bleeding

For TIPS placed for variceal hemorrhage, U.S. guidance recommends a goal PSG <12 mmHg or a 50%–60% reduction from the pre-TIPS gradient. Stent diameter alone should not be used as the procedural endpoint. These thresholds are best validated for esophageal varices. (Boike 2022)

Gastric or ectopic varices

Gastric and ectopic varices may bleed at lower gradients than esophageal varices, so a technically adequate drop in PSG does not always eliminate bleeding risk. In these settings, concurrent obliteration/embolization may still be needed. (Boike 2022, Lee 2024)

Refractory ascites or hepatic hydrothorax

For ascites/hydrothorax, current U.S. guidance does not endorse a single absolute PSG target. Instead, a staged approach is recommended:

  • start with an 8 mm controlled-expansion covered stent
  • reassess clinical response
  • dilate further only if needed, typically at ~6-week intervals (Boike 2022, Biggins 2021)

When TIPS is most often used

High-yield U.S.-supported indications

  • Pre-emptive TIPS within 72 hours in selected high-risk acute variceal hemorrhage:
  • Salvage/rescue TIPS for persistent or early recurrent bleeding despite vasoactive and endoscopic therapy (Lee 2024)
  • Elective TIPS for carefully selected refractory/recurrent ascites or hepatic hydrothorax (Biggins 2021, Boike 2022)
  • In variceal bleeding, concurrent variceal embolization/obliteration at the time of TIPS can reduce rebleeding. (Boike 2022)
  • In elective TIPS for ascites or hydrothorax, embolization of large spontaneous portosystemic shunts (>6 mm) may reduce post-TIPS encephalopathy risk. (Boike 2022)

Who is less likely to do well after TIPS

Patients usually do poorly after TIPS because of post-TIPS HE, post-TIPS liver failure, or cardiopulmonary decompensation rather than technical failure of the shunt. High-risk features include:

  • Advanced liver dysfunction: rising bilirubin, higher MELD, Child-Pugh C
  • Renal dysfunction
  • Hyponatremia
  • Prior overt HE
  • Advanced age
  • Frailty/sarcopenia
  • Cardiac dysfunction or pulmonary vascular disease (Biggins 2021, Boike 2022)

Major reasons to avoid elective TIPS

  • ACC/AHA stage C or D heart failure
  • Severe untreated valvular heart disease
  • Moderate-severe pulmonary hypertension
  • Uncontrolled systemic infection
  • Refractory overt HE
  • Unrelieved biliary obstruction
  • Unsafe anatomy for shunt creation (Boike 2022)

MELD and candidacy

  • There is no universal absolute MELD cutoff for elective TIPS in current U.S. guidance. (Boike 2022)
  • For refractory ascites, MELD ≥18 generally identifies patients who are poor candidates. (Biggins 2021)
  • For salvage/rescue bleeding, MELD >30, Child-Pugh ≥14, or lactate >12 mmol/L is near a futility zone unless TIPS is being used as a bridge to urgent transplant. (Lee 2024, Walter 2021)

Immediate and early procedural risks

Potential immediate or early complications include:

  • Bleeding
    • hemoperitoneum
    • capsular puncture
    • vascular injury
  • Hemobilia / biliary injury
  • Stent malposition
  • Accelerated liver failure
  • Rapid cardiac, pulmonary, or renal decompensation
  • Rarely, death (Yin 2022, Boike 2022)
  • U.S. recommendations do not specify a universal pre-TIPS INR or platelet target for cirrhosis patients. (Boike 2022)
  • Routine prophylactic antibiotics are not universally required; use depends on patient factors such as prior biliary instrumentation and local practice. (Boike 2022)
  • After TIPS, at minimum, patients should undergo overnight observation and routine day-after CBC, CMP, and PT/INR. (Boike 2022)

Delayed complications after TIPS

1) Hepatic encephalopathy

This is the most common important complication after TIPS.

  • Overt HE occurs in approximately 25%–50% of patients. (Boike 2022)
  • Risk is higher with:
    • prior overt HE
    • older age
    • Child-Pugh C / advanced liver dysfunction
    • renal dysfunction
    • hyponatremia
    • sarcopenia (Boike 2022)

Most post-TIPS HE can be treated medically with lactulose, then rifaximin if recurrent, but persistent or refractory HE may require TIPS diameter reduction. Severe refractory HE requiring shunt reduction occurs in about 8% of recipients. (Boike 2022)

2) Post-TIPS liver failure

TIPS can precipitate liver failure if the liver cannot tolerate reduced portal perfusion.

  • A commonly used proposed definition is ≥3-fold bilirubin and/or ≥2-fold INR increase within 30 days, especially when associated with clinical deterioration. (Gaba 2016, Mukund 2024)
  • Risk rises with higher baseline liver dysfunction and prior HE. (Mukund 2024, Biggins 2021)

3) Cardiac decompensation

Because TIPS increases venous return, it can unmask or worsen:

  • heart failure
  • diastolic dysfunction
  • pulmonary hypertension
  • right-sided pressure overload (Boike 2022)

4) TIPS dysfunction

Loss of decompression can occur from stenosis or occlusion, leading to recurrent bleeding, recurrent ascites, or rising gradient. Covered stents have reduced dysfunction compared with bare stents, but dysfunction still occurs. (Musto 2022, Boike 2022)

Pre-TIPS evaluation that most changes outcomes

Before elective TIPS, U.S. guidance emphasizes:

  • CBC, CMP, PT/INR, bilirubin, creatinine, sodium, MELD
  • Cross-sectional imaging to assess portal/hepatic vein patency and anatomy
  • Comprehensive echocardiography
  • Assessment for prior HE, frailty/sarcopenia, infection, biliary obstruction, and transplant trajectory (Boike 2022, Biggins 2021)

Cardiac thresholds that should slow or stop elective TIPS

  • Avoid elective TIPS if LVEF <50%
  • Avoid elective TIPS if grade III diastolic dysfunction
  • If RVSP >45 mmHg or TAPSE <1.6 cm, obtain further cardiology evaluation and often right-heart catheterization (Boike 2022)

Post-TIPS care and surveillance

  • Observe at least overnight after the procedure.
  • Obtain next-day labs to assess for bleeding, liver injury, renal dysfunction, and coagulopathy. (Boike 2022)
  • For covered stents, routine very early Doppler ultrasound is not universally recommended because early thrombosis is rare and Doppler has limited specificity for dysfunction. (Boike 2022)
  • Recurrent bleeding, recurrent ascites/hydrothorax, or Doppler findings concerning for stenosis should prompt TIPS venography and manometry. (Boike 2022)
  • Worsening confusion despite standard HE therapy
  • Rapid bilirubin rise or worsening INR
  • Dyspnea, edema, rising JVP, or hypoxemia after shunt creation
  • Recurrent bleeding or recurrent ascites despite a patent-appearing shunt
  • Need for repeated hospitalizations soon after TIPS

These patterns suggest that the problem may be overshunting, cardiac intolerance, post-TIPS liver failure, or shunt dysfunction, rather than inadequate procedural technique alone.

Practical bedside takeaways

  • TIPS works by decompressing portal pressure, but the “right” amount of decompression depends on the indication.
  • For variceal bleeding, target PSG <12 mmHg or 50%–60% reduction.
  • For ascites, there is no single fixed U.S. gradient target; start small and titrate to clinical response.
  • The most important complications are HE, liver failure, cardiac decompensation, and shunt dysfunction.
  • A technically successful TIPS can still be a clinical failure if the patient does not have enough liver, kidney, cardiac, or cognitive reserve.
  • In current U.S. guidance, MELD is a risk marker, not a universal elective contraindication, although MELD ≥18 should raise concern for elective ascites TIPS and MELD >30 is near-futile territory in salvage bleeding TIPS unless transplant is imminent. (Biggins 2021, Boike 2022, Lee 2024, Walter 2021)

References

Last Edited 03/22/2026